Top Markets
#1 Black Phoenix Black Phoenix +860.29%
#2 QuantixAI QuantixAI +102.63%
#3 MetaDAO MetaDAO +26.72%
#4 Pons Pons +23.08%
#5 LayerZero LayerZero +20.52%
#6 Ontology Gas Ontology Gas +19.80%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +19.11%
#8 Bedrock Bedrock +18.57%
#9 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +18.04%
#10 SPX6900 SPX6900 +15.41%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Immunovant, Inc. Immunovant, Inc.

Immunovant, Inc.

IMVT
Rangering i aksjer #2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Aksjekurs
$43.48
Markedsverdi
$8.97B
Endring (1 dag)
0.37%
Endring (1 år)
192.01%
Land
US
Handel Immunovant, Inc. (IMVT)

Kategori

Healthcare
Inntekter for Immunovant, Inc. (IMVT)
Inntekter i 2026 TTM: 0
Ifølge Immunovant, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Immunovant, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH